Alzamend Neuro (NASDAQ:ALZN – Get Free Report) will likely be posting its Q4 2026 results before the market opens on Tuesday, July 28th. Analysts expect the company to post earnings of ($0.67) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2026 earning summary page for the latest details on the call scheduled for Friday, July 31, 2026 at 4:00 PM ET.
Alzamend Neuro Trading Up 4.1%
Shares of ALZN opened at $1.26 on Tuesday. Alzamend Neuro has a 1-year low of $0.84 and a 1-year high of $3.35. The firm’s 50-day moving average price is $1.17 and its 200-day moving average price is $1.52. The firm has a market capitalization of $4.79 million, a price-to-earnings ratio of -0.58 and a beta of 0.14.
Wall Street Analyst Weigh In
Separately, Weiss Ratings raised Alzamend Neuro from a “sell (e)” rating to a “sell (e+)” rating in a research report on Monday, June 29th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $28.00.
Hedge Funds Weigh In On Alzamend Neuro
An institutional investor recently raised its stake in Alzamend Neuro stock. Geode Capital Management LLC grew its holdings in Alzamend Neuro, Inc. (NASDAQ:ALZN – Free Report) by 33.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 27,506 shares of the company’s stock after acquiring an additional 6,928 shares during the period. Geode Capital Management LLC owned 0.72% of Alzamend Neuro worth $50,000 as of its most recent SEC filing. Institutional investors own 49.61% of the company’s stock.
Alzamend Neuro Company Profile
Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
Featured Stories
- Five stocks we like better than Alzamend Neuro
- The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
- Is Domino’s Stock Serving Up a Buying Opportunity?
- A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free
- Why Gold Miners Could Be the Market’s Biggest Comeback Story
Receive News & Ratings for Alzamend Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alzamend Neuro and related companies with MarketBeat.com's FREE daily email newsletter.
